ALPMF (Astellas Pharma) Institutional Ownership: 42.59% (As of Jul. 09, 2026)


ALPMF Astellas Pharma Inc ALPMF
72 GF Score
Price $12.85
GF Value $14.19
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Institutional Ownership?

Astellas Pharma ALPMF -11.99% 72 Institutional Ownership is 42.59% as of Jul. 09, 2026. GuruFocus rates ALPMF with a GF Score™ of 72/100 and a GF Value™ of $14.19 (Fairly Valued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Astellas Pharma's institutional ownership is 42.59%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Astellas Pharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Astellas Pharma's Float Percentage Of Total Shares Outstanding is 0.00%.

Astellas Pharma Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Institutional Ownership Chart

Astellas Pharma Historical Data

The historical data trend for Astellas Pharma can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 40.06 40.72 41.92 43.21 43.48 44.59 44.45 44.41 44.40 44.60
ALPMF
72GF Score
Astellas Pharma Inc ALPMF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 42.59% mean?
Astellas Pharma (ALPMF) has a Institutional Ownership of 42.59% as of Jul. 09, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Institutional Ownership too high?
Astellas Pharma's current Institutional Ownership is 42.59%. Overall, Astellas Pharma has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Institutional Ownership compare to LLY and JNJ?
Astellas Pharma's Institutional Ownership of 42.59% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Institutional Ownership is 42.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.19, compared to a current price of $12.85 — trading 9.4% below its estimated fair value. The current Institutional Ownership is 42.59%. Astellas Pharma's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Institutional Ownership is 42.59% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of $12.85 is trading 9.4% below its estimated GF Value™ of $14.19. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for ALPMF:

  • Institutional Ownership: 42.59%
  • GF Value™: $14.19 vs. price of $12.85 (9.4% below fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
72GF Score

Get the complete analysis for ALPMF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.85
Price
$14.19
GF Value